Diagnostics /

NGAL for routine diagnostics of acute kidney injury*

NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). Under normal conditions NGAL levels are low in urine and plasma but rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.

Clinical research have proven that NGAL levels identify patients with AKI before any diagnostic change in serum creatinine.
The existing clinical evidence points to several benefits of NGAL testing such as -

  • Early diagnosis of AKI to allow earlier initiation of appropriate management
  • Risk stratification of AKI
  • Prediction of clinical outcomes (dialysis, in-hospital death, length of hospital stay, mortality)
  • Monitor response to therapy
  • Lower hospitalization costs

What is NGAL?

NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.

*For in vitro diagnostic use in the European Union, Canada, Chile, Columbia, India, Korea, Russia and Israel only. For research use only in all other markets.